2,790,698 Shares in ProMIS Neurosciences, Inc. (NASDAQ:PMN) Purchased by Great Point Partners LLC

Great Point Partners LLC bought a new position in ProMIS Neurosciences, Inc. (NASDAQ:PMN) in the third quarter, HoldingsChannel reports. The fund bought 2,790,698 shares of the company’s stock, valued at approximately $3,488,000. ProMIS Neurosciences makes up about 1.0% of Great Point Partners LLC’s portfolio, making the stock its 25th largest position. Great Point Partners LLC owned approximately 0.09% of ProMIS Neurosciences as of its most recent filing with the SEC.

Insider Buying and Selling

In other news, Director Madge K. Shafmaster bought 70,000 shares of ProMIS Neurosciences stock in a transaction that occurred on Monday, September 23rd. The stock was bought at an average cost of $1.28 per share, with a total value of $89,600.00. Following the acquisition, the director now owns 138,333 shares of the company’s stock, valued at $177,066.24. The trade was a 102.44 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.40% of the stock is currently owned by insiders.

ProMIS Neurosciences Price Performance

NASDAQ PMN opened at $0.92 on Wednesday. ProMIS Neurosciences, Inc. has a 52 week low of $0.88 and a 52 week high of $3.10. The firm has a market capitalization of $30.07 million, a P/E ratio of -9.20 and a beta of 0.60. The company has a 50-day moving average price of $1.08 and a 200-day moving average price of $1.42.

About ProMIS Neurosciences

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.